Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector Inc (Nasdaq: ALEC) announced presentations on its TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®). The event will be held online and in Philadelphia from July 28 to August 1, 2024.
Key presentations include:
- Two posters on the AL002 TREM2 program, developed with AbbVie, focusing on the INVOKE-2 phase 2 study in early Alzheimer's disease.
- Three posters on progranulin programs (latozinemab and AL101/GSK4527226), developed with GSK, covering plasma biomarkers, the PROGRESS-AD phase 2 study, and genetics related to Alzheimer's disease.
These presentations highlight Alector's ongoing efforts in immuno-neurology and Alzheimer's disease research.
Alector (Nasdaq: ALEC), a clinical-stage biotechnology company specializing in immuno-neurology, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024. The event will be held virtually, and Alector's management will participate in a corporate presentation. Interested parties can access the webcast on the 'Events & Presentations' page of the Alector website starting at 7:00 a.m. ET. A replay of the presentation will be available on the website for 90 days post-event.
Alector, a clinical-stage biotech firm specializing in immuno-neurology, is set to host a virtual Research and Development event on June 18, 2024. The event will highlight the Alector Brain Carrier, a novel blood-brain barrier (BBB) technology platform. This platform is integral to the company’s upcoming product candidates and research initiatives. The session will feature insights from Alector's management and Dr. Zhiqiang An, an expert in BBB modulation. Participants can register on Alector's website, and a live Q&A will follow the presentation. A replay will be accessible for 90 days post-event.
Alector (Nasdaq: ALEC), a clinical-stage biotechnology company specializing in immuno-neurology, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled for Monday, June 10, 2024, at 1:20 p.m. ET. A live webcast will be accessible via the Investors section of Alector's website, with a replay available for 90 days post-event.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company, will be participating in the Bank of America Securities Health Care Conference and H.C. Wainwright 2nd Annual BioConnect Investor Conference. The company's management will give presentations at these events, showcasing their work in immuno-neurology. Webcasts of the presentations will be available on the Alector website.
Alector, Inc. (Nasdaq: ALEC) reported Q1 2024 financial results with $562.1 million in cash. The company is advancing its pipeline, strengthening leadership, and expects a data readout from the INVOKE-2 Phase 2 clinical trial of AL002 for early Alzheimer’s disease in Q4 2024. Alector also has a pivotal Phase 3 trial of latozinemab in FTD-GRN and a Phase 2 trial of AL101/GSK4527226 in early AD ongoing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.